Merck & Company News - August 2026
🟢 Merck is trading 3.11% up today after cancer vaccine met both Phase 3 endpoints
Merck is trading at $153.63 (+3.11%) after its jointly developed cancer vaccine with Moderna met both Phase 3 melanoma endpoints. - INTerpath-001 showed...
🟢 Merck is trading 10% up today after positive Phase 3 melanoma vaccine results
Merck is trading 10.44% up now at $149.42 after Merck and Moderna announced positive Phase 3 INTerpath-001 results for intismeran combined with Keytruda. -...
🟢 Merck is trading 12% up today after positive Phase 3 melanoma vaccine results
Merck is trading at $151.09 (+11.74%) after Merck and Moderna reported positive Phase 3 results for personalized mRNA cancer vaccine intismeran combined with...
Merck's mRNA Cancer Vaccine Breakthrough Sends Shares Surging — But Can a Personalized Shot Offset a $32 Billion Patent Cliff?
Shares of Merck vaulted 10% to $148.64 Wednesday morning after the pharma giant and partner Moderna reported that their personalized mRNA cancer vaccine hit...
🟢 Merck is trading 9.39% up today after positive Phase 3 personalized mRNA melanoma vaccine results
Merck is trading 9.39% up at $148.64 after Merck and Moderna announced positive Phase 3 results for their personalized mRNA melanoma vaccine. - Combined with...
Merck's second quarter revenue of $16.6B beat estimates, driven by strong Keytruda sales and an upgraded FY2026 outlook.
Merck reported second quarter 2026 revenue of $16.6 billion, a 5% year-over-year increase that surpassed analyst expectations. The company posted a non-GAAP...
Merck & Company Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Merck & Company is expected to report Q2 2026 revenue of $16.33 billion and a consensus EPS loss of $0.26, while the current $130.20 share price sits below the...